Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 154 No. 2 (2024)

Therapeutic management of fibrosis in systemic sclerosis patients – an analysis from the Swiss EUSTAR cohort

  • Kevin Windirsch
  • Suzana Jordan
  • Mike Oliver Becker
  • Cosimo Bruni
  • Rucsandra Dobrota
  • Muriel Elhai
  • Ion-Alexandru Garaiman
  • Carmen-Marina Mihai
  • Michele Iudici
  • Paul Hasler
  • Camillo Ribi
  • Britta Maurer
  • Armando Gabrielli
  • Anna-Maria Hoffmann-Vold
  • Oliver Distler
DOI
https://doi.org/10.57187/s.3630
Cite this as:
Swiss Med Wkly. 2024;154:3630
Published
06.02.2024

Summary

OBJECTIVES: Systemic sclerosis is a chronic autoimmune connective tissue disease leading to microvascular and fibrotic manifestations in multiple organs. Several treatment options and recommendations from different European countries are available. In this study, for which the ambit is Switzerland specifically, we aim to describe the treatment patterns of systemic sclerosis patients with fibrotic manifestations.

METHODS: Systemic sclerosis patients were selected from six Swiss tertiary centres recorded in the multicentre, prospective European Scleroderma Trials and Research (EUSTAR) registry. Patients fulfilling the 2013 ACR/EULAR systemic sclerosis classification criteria at baseline were included. To determine the differences in treatment of varying degrees of fibrosis, four groups were identified: (1) patients with a modified Rodnan skin score (mRSS) >0; (2) those with mRSS ≥7; (3) those with interstitial lung disease (SSc-ILD), diagnosed by either chest X-Ray or high-resolution computed tomography; and (4) patients fulfilling one of the additional criteria for extensive interstitial lung disease, defined as interstitial lung disease involvement of >20% in high-resolution computed tomography, dyspnea NYHA-stage 3/4, or a predicted forced vital capacity (FVC) of <70%.

RESULTS: A total of 590 patients with systemic sclerosis fulfilled the inclusion criteria. In this cohort, 421 (71.4%) had mRSS >0, of whom 195 (33.1%) had mRSS ≥7; interstitial lung disease was diagnosed in 198 of 456 (43.4%), of whom 106 (18.0 %) showed extensive interstitial lung disease. Regarding non-biologic disease-modifying medications (DMARDs), the most frequently prescribed was methotrexate, followed by hydroxychloroquine and mycophenolate mofetil. Rituximab and tocilizumab were most frequently used among the biologic DMARDs. Specifically, 148/372 (39.8%) of treated patients with skin fibrosis received methotrexate, mycophenolate mofetil or rituximab, and 80/177 (45.2%) with interstitial lung disease received cyclophosphamide, mycophenolate mofetil, tocilizumab or rituximab. Most patients received a proton-pump inhibitor, and few patients underwent hematopoietic stem cell transplantation.

CONCLUSION: Overall, in Switzerland, a wide range of medications is prescribed for systemic sclerosis patients. This includes modern, targeted treatments for which randomised controlled clinical trial have been recently reported.

References

  1. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017 Oct;390(10103):1685–99. 10.1016/S0140-6736(17)30933-9 DOI: https://doi.org/10.1016/S0140-6736(17)30933-9
  2. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009 May;360(19):1989–2003. 10.1056/NEJMra0806188 DOI: https://doi.org/10.1056/NEJMra0806188
  3. Wollheim FA. Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford). 2005 Oct;44(10):1212–6. 10.1093/rheumatology/keh671 DOI: https://doi.org/10.1093/rheumatology/keh671
  4. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013 Nov;65(11):2737–47. 10.1002/art.38098
  5. Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol. 2011;6(1):509–37. 10.1146/annurev-pathol-011110-130312 DOI: https://doi.org/10.1146/annurev-pathol-011110-130312
  6. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al.; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327–39. 10.1136/annrheumdis-2016-209909
  7. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al.; EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009 May;68(5):620–8. 10.1136/ard.2008.096677 DOI: https://doi.org/10.1136/ard.2008.096677
  8. Denton CP, Hughes M, Gak N, Vila J, Buch MH, Chakravarty K, et al.; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford). 2016 Oct;55(10):1906–10. 10.1093/rheumatology/kew224 DOI: https://doi.org/10.1093/rheumatology/kew224
  9. Hachulla E, Agard C, Allanore Y, Avouac J, Bader-Meunier B, Belot A, et al.; Collaborators. French recommendations for the management of systemic sclerosis. Orphanet J Rare Dis. 2021 Jul;16(S2 Suppl 2):322. 10.1186/s13023-021-01844-y DOI: https://doi.org/10.1186/s13023-021-01844-y
  10. Hoffmann-Vold AM (Rheumatology L, editor). Distler O et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. 2020. pp. E71–83. 10.1016/S2665-9913(19)30144-4
  11. van den Hoogen FHJ, Boerbooms AMT, Swaak AJG, Rasker JJ, van Lier HJJ, van de Putte LBA. Comparison of Methotrexate with placebo in the treatment of systemic sclerosis: a 24 Week randomized double-blind trial, followed by a 24 week observational trial. 1996;35:364–72. DOI: https://doi.org/10.1093/rheumatology/35.4.364
  12. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001 Jun;44(6):1351–8. 10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I DOI: https://doi.org/10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I
  13. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006 Dec;54(12):3962–70. 10.1002/art.22204 DOI: https://doi.org/10.1002/art.22204
  14. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al.; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun;354(25):2655–66. 10.1056/NEJMoa055120
  15. Volkmann ER, Tashkin DP, Sim M, Li N, Khanna D, Roth MD, et al. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. J Rheumatol. 2019 Oct;46(10):1316–25. 10.3899/jrheum.180441 DOI: https://doi.org/10.3899/jrheum.180441
  16. Namas R, Tashkin DP, Furst DE, Wilhalme H, Tseng CH, Roth MD, et al.; Participants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. Arthritis Care Res (Hoboken). 2018 Mar;70(3):439–44. 10.1002/acr.23282 DOI: https://doi.org/10.1002/acr.23282
  17. Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, et al. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol. 2017 Jul;69(7):1451–60. 10.1002/art.40114 DOI: https://doi.org/10.1002/art.40114
  18. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al.; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun;354(25):2655–66. 10.1056/NEJMoa055120
  19. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al.; Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Sep;4(9):708–19. 10.1016/S2213-2600(16)30152-7
  20. Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016 Jun;387(10038):2630–40. 10.1016/S0140-6736(16)00232-4 DOI: https://doi.org/10.1016/S0140-6736(16)00232-4
  21. Khanna D, Lin CJ, Furst DE, Goldin J, Kim G, Kuwana M, et al.; focuSSced investigators. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020 Oct;8(10):963–74. 10.1016/S2213-2600(20)30318-0
  22. Distler O, Distler JH. Tocilizumab for systemic sclerosis: implications for future trials. Lancet. 2016 Jun;387(10038):2580–1. 10.1016/S0140-6736(16)00622-X DOI: https://doi.org/10.1016/S0140-6736(16)00622-X
  23. Kuster S, Jordan S, Elhai M, Held U, Steigmiller K, Bruni C, et al.; EUSTAR collaborators. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD Open. 2022 Nov;8(2):e002477. 10.1136/rmdopen-2022-002477 DOI: https://doi.org/10.1136/rmdopen-2022-002477
  24. Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, et al.; RECITAL Investigators. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023 Jan;11(1):45–54. 10.1016/S2213-2600(22)00359-9
  25. Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017 Jun;18(1):275. 10.1186/s13063-017-2016-2 DOI: https://doi.org/10.1186/s13063-017-2016-2
  26. al SEe. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double blind, investigators-initiated, randomised, placebo-controlled trial. Lancet Rheumatology. 2022;Volume 4, Issue 8, E546-E555, August 2022. DOI: https://doi.org/10.1016/S2665-9913(22)00131-X
  27. Tsukamoto H, Nagafuji K, Horiuchi T, Mitoma H, Niiro H, Arinobu Y, et al. Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells. Rheumatology (Oxford). 2011 May;50(5):944–52. 10.1093/rheumatology/keq414 DOI: https://doi.org/10.1093/rheumatology/keq414
  28. Vonk MC, Marjanovic Z, van den Hoogen FH, Zohar S, Schattenberg AV, Fibbe WE, et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis. 2008 Jan;67(1):98–104. 10.1136/ard.2007.071464 DOI: https://doi.org/10.1136/ard.2007.071464
  29. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011 Aug;378(9790):498–506. 10.1016/S0140-6736(11)60982-3 DOI: https://doi.org/10.1016/S0140-6736(11)60982-3
  30. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al.; EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014 Jun;311(24):2490–8. 10.1001/jama.2014.6368
  31. Hernández J, Jordan S, Dobrota R, Iudici M, Hasler P, Ribi C, et al.; The Eustar Collaborators. The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort. Swiss Med Wkly. 2021 Jul;151(2728):w20528. 10.4414/smw.2021.20528 DOI: https://doi.org/10.4414/smw.2021.20528
  32. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000 Mar;132(6):425–34. 10.7326/0003-4819-132-6-200003210-00002 DOI: https://doi.org/10.7326/0003-4819-132-6-200003210-00002
  33. Dobrota R, Maurer B, Graf N, Jordan S, Mihai C, Kowal-Bielecka O, et al.; EUSTAR coauthors. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. Ann Rheum Dis. 2016 Oct;75(10):1743–8. 10.1136/annrheumdis-2015-208024 DOI: https://doi.org/10.1136/annrheumdis-2015-208024
  34. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008 Jun;177(11):1248–54. 10.1164/rccm.200706-877OC DOI: https://doi.org/10.1164/rccm.200706-877OC
  35. Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2017 Apr;46(5):625–31. 10.1016/j.semarthrit.2016.10.003 DOI: https://doi.org/10.1016/j.semarthrit.2016.10.003
  36. Bandeira CD, Rubin AS, Cardoso PF, Moreira JS, Machado MM. Prevalence of gastroesophageal reflux disease in patients with idiopathic pulmonary fibrosis. J Bras Pneumol. 2009 Dec;35(12):1182–9. 10.1590/S1806-37132009001200004 DOI: https://doi.org/10.1590/S1806-37132009001200004
  37. Qi J, Shang S, Li Z, Kang J, Kong L. [The relationship between idiopathic pulmonary fibrosis and gastroesophageal reflux disease]. Zhonghua Nei Ke Za Zhi. 2015 Aug;54(8):695–8.
  38. Wu W, Jordan S, Becker MO, Dobrota R, Maurer B, Fretheim H, et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann Rheum Dis. 2018 Sep;77(9):1326–32. 10.1136/annrheumdis-2018-213201 DOI: https://doi.org/10.1136/annrheumdis-2018-213201
  39. Shenoy PD, Bavaliya M, Sashidharan S, Nalianda K, Sreenath S. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis. Arthritis Res Ther. 2016 Jun;18(1):123. 10.1186/s13075-016-1015-0 DOI: https://doi.org/10.1186/s13075-016-1015-0
  40. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30(2 Suppl 71):S17–22.
  41. Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, et al.; EUSTAR Rituximab study group. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015 Jun;74(6):1188–94. 10.1136/annrheumdis-2013-204522 DOI: https://doi.org/10.1136/annrheumdis-2013-204522
  42. Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, et al.; for EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019 Jul;78(7):979–87. 10.1136/annrheumdis-2018-214816 DOI: https://doi.org/10.1136/annrheumdis-2018-214816
  43. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010 Feb;49(2):271–80. 10.1093/rheumatology/kep093 DOI: https://doi.org/10.1093/rheumatology/kep093
  44. Ebata S, Yoshizaki-Ogawa A, Sato S, Yoshizaki A. New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. J Clin Med. 2022 Aug;11(15):4631. 10.3390/jcm11154631 DOI: https://doi.org/10.3390/jcm11154631
  45. Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018 Dec;57(12):2106–13. 10.1093/rheumatology/key213 DOI: https://doi.org/10.1093/rheumatology/key213
  46. Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2022. DOI: https://doi.org/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A4779
  47. Khanna D, Denton CP, Lin CJ, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018 Feb;77(2):212–20. 10.1136/annrheumdis-2017-211682 DOI: https://doi.org/10.1136/annrheumdis-2017-211682
  48. Khanna D, Lin CJ, Furst DE, Goldin J, Kim G, Kuwana M, et al. A randomised placebo-controlled phase 3 trial of tocilizumab in systemic sclerosis. Lancet Respir Med. 2020. 10.1016/S2213-2600(20)30318-0
  49. Hunzelmann N, Moinzadeh P, Genth E, Krieg T, Lehmacher W, Melchers I, et al.; German Network for Systemic Scleroderma Centers. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther. 2009;11(2):R30. 10.1186/ar2634 DOI: https://doi.org/10.1186/ar2634
  50. Iudici M, Fasano S, Iacono D, Russo B, Cuomo G, Valentini G. Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries. Clin Rheumatol. 2014 Feb;33(2):153–64. 10.1007/s10067-013-2422-0 DOI: https://doi.org/10.1007/s10067-013-2422-0
  51. Salaffi F, Di Carlo M, Carotti M, Fraticelli P, Gabrielli A, Giovagnoni A. Relationship between interstitial lung disease and oesophageal dilatation on chest high-resolution computed tomography in patients with systemic sclerosis: a cross-sectional study. Radiol Med. 2018 Sep;123(9):655–63. 10.1007/s11547-018-0894-3 DOI: https://doi.org/10.1007/s11547-018-0894-3
  52. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al.; SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 Jun;380(26):2518–28. 10.1056/NEJMoa1903076 DOI: https://doi.org/10.1056/NEJMoa1903076
  53. Valentini G, D’Angelo S, Della Rossa A, Bencivelli W, Bombardieri S. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis. 2003 Sep;62(9):904–5. 10.1136/ard.62.9.904 DOI: https://doi.org/10.1136/ard.62.9.904

Most read articles by the same author(s)

1 2 > >>